Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

GlaxoSmithKline reports positive results from phase III trial of its two-drug HIV treatment

The GEMINI trials showed that HIV could be treated with a two-drug regimen, as opposed to the cocktail of three or more drugs which sufferers currently have to take
aids patient in doctors
Fewer drugs should mean fewer side effects, scientists reckon

GlaxoSmithKline plc’s (LON:GSK) majority-owned ViiV Healthcare division has reported positive results from two phase III studies of its two-drug HIV treatment.

Currently, HIV sufferers have to take a cocktail of drugs every day to keep the virus at bay but GSK, along with others, have been working on new treatments that contain fewer drugs and can be taken less frequently.

Results from the GEMINI-1 and GEMINI-2 studies have shown that the two-drug regimen of dolutegravir and lamivudine is just as effective as the standard three-drug regimen of dolutegravir and two nucleoside reverse transcriptase inhibitors.

READ: GSK's two drug, one pill HIV treatment gets green light

Besides making life easier for HIV patients, scientists believe that having to take fewer medicines will lead to fewer side effects.

“The GEMINI studies demonstrate the potency, safety and tolerability of the dolutegravir plus lamivudine combination,” said ViiV’s chief medical officer John Pottage.

“They affirm our two-drug regimen strategy and reinforce our belief that many patients can control their disease with two drugs instead of three or more.

He added: “Importantly, the studies show that this two-drug regimen could be an option for treatment naïve patients and can support a broad range of patients living with HIV around the world.”

Full results from the studies will be presented at an upcoming meeting and ViiV said it will now plan for regulatory submissions for the two-drug regimen later this year.

"We believe this is an important boost to GSK’s longer term position in HIV vs Gilead but expect the share reaction to be more muted given consensus scepticism on duals’ adoption without long term data on resistance," said Liberum analyst Graham Doyle.

Shares rose 1.3% to £15.65 in early deals.

--Updates for analyst comment and share price--

View full GSK profile View Profile

GlaxoSmithKline plc Timeline

Related Articles

Skin beauty
April 19 2018
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019
surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use